EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Pharmacokinetics and pharmacodynamics of desoxycorticosterone pivalate in dogs with hypoadrenocorticism

Daniel K Langlois iD, Levent Dirikolu, Jean M Brudvig, Andreas F Lehner, Laurie L Nelms, Stephan A Carey, Sara A Jablonski, Harry Cridge, Enass Bassiouny, Justin Zyskowski, John P Buchweitz iD

Journal of Veterinary Internal Medicine · 21.01.2026 · 40 (1)

DOI: 10.1093/jvimsj/aalaf003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Veterinary Internal Medicine, online erschienen am 21.01.2026. Verfasst von Daniel K Langlois und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, MI 48824, United States. Hauptthemen laut MEDLINE: Adrenal Insufficiency, Desoxycorticosterone, Dog Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Stanton Foundation Spectrum of Care Clinical Research Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Desoxycorticosterone pivalate (DOCP) is commonly used to treat mineralocorticoid deficiency in dogs with hypoadrenocorticism (HA). Hypothesis/Objective To determine the pharmacokinetics and pharmacodynamics of DOCP. Animals Twenty-one dogs with newly diagnosed HA.

Methods

Prospective clinical trial. Dogs were randomly assigned to treatment with an SC injection of either 1.1 mg/kg (low-dose) or 2.2 mg/kg (label-dose) DOCP. Blood samples were collected at set time points for measurement of serum drug concentrations, serum electrolyte concentrations, and plasma renin activities (PRAs). A one-compartment model was used to determine pharmacokinetics variables. Pharmacodynamics variables including duration of DOCP action and duration of overtreatment were estimated from serum electrolyte concentrations and PRA. Pharmacokinetics and pharmacodynamics variables were compared between low-dose and label-dose groups.

Results

Maximum drug concentrations and overall drug exposures were higher in label-dose dogs (1.22 ± 0.46 ng/mL and 32.1 ± 12.3 day × ng/mL) than in low-dose dogs (0.69 ± 0.32 ng/mL and 19.6 ± 5.3 day × ng/mL; P = .008 for both comparisons). However, duration of DOCP action as determined by PRA in label-dose (55 ± 16 days) and low-dose (45 ± 12 days) dogs was not different (P = .2). Serum electrolyte concentrations overestimated the duration of action in the combined group by a mean of 10 days when compared with PRA (P < .001). Conclusions and clinical importance Pharmacokinetics and pharmacodynamics data suggest that low-dose DOCP administered every 5-7 weeks is a reasonable treatment strategy for most dogs with HA. Prolonging dosing intervals > 7-8 weeks based solely on electrolyte concentrations should be avoided.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenal InsufficiencyDesoxycorticosteroneDog DiseasesAnimalsDogsFemaleMaleDose-Response Relationship, DrugElectrolytesProspective StudiesRenin

Stichwörter der Autor:innen

Addison’s diseaseZycortaladrenal insufficiencyaldosteronetreatment

Substanzen

deoxycortone pivalateDesoxycorticosteroneElectrolytesRenin

Autor:innen und Institutionen

  • Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, MI 48824, United States.
  • Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, United States.
  • Veterinary Diagnostic Laboratory, College of Veterinary Medicine, Michigan State University, East Lansing, MI 48910, United States.
  • Greater Lansing Veterinary Center, Williamston, MI 48895, United States.
  • Department of Pathobiology and Diagnostic Investigation, College of Veterinary Medicine, Michigan State University, East Lansing, MI 48824, United States.

ORCID-Profile: Daniel K Langlois, John P Buchweitz

Förderung

  • Stanton Foundation Spectrum of Care Clinical Research Program

Zitieren

APA

Langlois, D. K., Dirikolu, L., Brudvig, J. M., Lehner, A. F., Nelms, L. L., Carey, S. A., Jablonski, S. A., Cridge, H., Bassiouny, E., Zyskowski, J., & Buchweitz, J. P. (2026). Pharmacokinetics and pharmacodynamics of desoxycorticosterone pivalate in dogs with hypoadrenocorticism. Journal of Veterinary Internal Medicine, 40(1). https://doi.org/10.1093/jvimsj/aalaf003

Vancouver

Langlois DK, Dirikolu L, Brudvig JM, Lehner AF, Nelms LL, Carey SA, et al. Pharmacokinetics and pharmacodynamics of desoxycorticosterone pivalate in dogs with hypoadrenocorticism. Journal of Veterinary Internal Medicine. 2026;40(1). doi:10.1093/jvimsj/aalaf003

BibTeX
@article{Langlois2026,
  author = {Langlois, Daniel K and Dirikolu, Levent and Brudvig, Jean M and Lehner, Andreas F and Nelms, Laurie L and Carey, Stephan A and Jablonski, Sara A and Cridge, Harry and Bassiouny, Enass and Zyskowski, Justin and Buchweitz, John P},
  title = {Pharmacokinetics and pharmacodynamics of desoxycorticosterone pivalate in dogs with hypoadrenocorticism},
  journal = {Journal of Veterinary Internal Medicine},
  year = {2026},
  volume = {40},
  number = {1},
  doi = {10.1093/jvimsj/aalaf003}
}
Kostenlos starten →